NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Mind Medicine Inc. is pleased to announce that it has closed its previously announced bought deal private placement offering . In connection with the Offering, the Company issued 6.0 million units of the Company at a price per Unit of CAD $3.25 for gross proceeds of CAD $19.5 million . The Offering was conducted by ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF, DE: MMQ) ("MindMed" or the "Company") is pleased to announce that it has closed its previously announced bought deal private placement offering (the "Offering"). In connection with the Offering, the Company issued 6.0 million units of the Company (the "Units") at a price per Unit of CAD $3.25 (the "Issue Price") for gross proceeds of CAD $19.5 million . The Offering was conducted by Canaccord Genuity Corp. (the "Underwriter") pursuant to an underwriting agreement dated March 9, 2021 between the Company and the Underwriter.

MindMed is a leading psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness. Following the closing of the Offering, the Corporation's cash on hand has increased to CAD $205.2 million (USD $162.0 million ). Since the founding of Mind Medicine, Inc. in May 2019 , MindMed has now raised a total of approximately CAD $256.7 million (USD $202.7 million ) in investment capital before fundraising and deal expenses, making it one of the leaders in the psychedelic medicine industry in its ability to finance its innovative R&D, a new digital therapeutics division and a growing clinical trial pipeline.

MindMed Co-Founder & CEO, J.R. Rahn said, "As we march forward with our uplisting plans for Nasdaq and the overall advancement of the MindMed portfolio, we saw it as a timely opportunity to bring in a strategic investor to support MindMed's future growth initiatives. In the years ahead, I believe MindMed will be viewed as much as a digital medicine platform as it is a pharmaceutical drug development company."

The net proceeds of the Offering will be used for further investment in Project Lucy (experiential LSD), the Microdose LSD Program and Project Albert, which is  now integrating MindMed's most recent technology acquisition, HealthMode, to build a comprehensive mental health platform to deploy psychedelics medicines, and for general working capital purposes.

Further Details of Offering

In connection with the Offering, the Company issued 6.0 million Units at the Issue Price for gross proceeds of CAD $19.5 million .

Each Unit comprises one subordinate voting share of the Company (each, a "Subordinate Voting Share") and one-half of one Subordinate Voting Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase one Subordinate Voting Share at an exercise price of CAD $4.40 until March 9, 2024 . If, at any time following the date that is four months and one day following the closing of the Offering, the daily volume weighted average trading price of the Subordinate Voting Shares on the Neo Exchange Inc. is greater than CAD $6.90 per Subordinate Voting Share for the preceding five consecutive trading days, the Company may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is at least 30 days following the date of such written notice.

The Subordinate Voting Shares and Warrants underlying the Units issued pursuant to the Offering are subject to a hold period of four months and one day following the closing of the Offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933 , as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933 , as amended, and applicable state securities laws.

About MindMed

MindMed is a leading psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the Company's groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

MindMed trades on the Neo Exchange Inc. under the symbol MMED . MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ . For more information: www.mindmed.co .

Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the intended use of proceeds of the Offering, the Company's cash reserves and the effects thereof, and the Company's intended future business plans and operations, including the development of psychedelic inspired medicines and experiential therapies. There are numerous risks and uncertainties that could cause actual results and MindMed's plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Media Contact: mindmed@150bond.com

SOURCE Mind Medicine (MindMed) Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2021/09/c3931.html

News Provided by Canada Newswire via QuoteMedia

Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6968839, titled: STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION), covering the composition of matter for SLS-007, a potentially disease-modifying gene therapy focused on intracellular alpha-synuclein (α-synuclein) aggregation in Parkinson's disease (PD).

Keep reading... Show less
Awakn Life Sciences to Participate at Upcoming December Conferences

Awakn Life Sciences to Participate at Upcoming December Conferences

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, is scheduled to present at the following upcoming virtual December investor conferences.

H.C. Wainwright 2nd Annual Psychedelics Conference
Presentation: On Demand Beginning Monday, December 6th at 7:00 a.m. ET
Registration: Click here

Keep reading... Show less

Michael Falvey joins COMPASS Pathways as Chief Financial Officer

London, UK - 3 December 2021

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Michael Falvey as Chief Financial Officer, replacing Piers Morgan when he leaves the company, as previously announced, at the end of the year.

Keep reading... Show less
Gwella logo

Gwella Mushrooms: Alternative Wellness Platform for Functional Health, Mushrooms and Psychedelics

Gwella focuses on building an accessible, original and scalable over-the-counter portfolio of functional and psychedelic mushroom products that enhance individual and community wellness. The company's advanced direct-to-consumer platform combines an innovative mix of wellness, mushrooms and psychedelics with a modern twist in an integration of media and technology.

Gwella Wellness is the company's purpose-built consumer product vertical. Using exclusive ingredients, formulations, delivery systems, testing and research, Gwella Branded CPG tackles health and wellness through high volume avenues in retail, e-commerce and clinical, retreat and legal jurisdictions. Its product pipeline includes Gwella's flagship Mojo, Journey, and incoming MYMYCO, Yugen and Anxiety Strips, with more products in development.

Keep reading... Show less
NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference

NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference

NeonMind Biosciences Inc. (CSE:NEON) (OTCQB:NMDBF) (FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that Robert Tessarolo, President and Chief Executive Officer, will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference, being held virtually on Monday, December 6, 2021

H.C. Wainwright 2nd Annual Psychedelics Virtual Conference Details:

Keep reading... Show less
man in suit stands in front of an audience

Psychedelics Business Joins Lift Expo Comeback

The Lift & Co. Expo recently made its grand return to Toronto — only this time the event added a psychedelics business portion to its traditionally cannabis-focused lineup.

For the first time since the show took hold as the de facto premier Canadian industry conference for cannabis stakeholders, event organizers decided to include the newest darling of the investment market.

The Lift Business Summit was a full day event that took place November 19. The event consisted of a packed day revolving around the world of psychedelics and the future of the sector.

Keep reading... Show less

Top News

Related News